Janssen
CARVYKTI
Manufacturer:
Janssen
Name:
CARVYKTI
HCPCS Code Descriptor:
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Category:
Q Code
HCPCS:
Q2056
NDC(s):
57894-0111-02, 57894-0111-01
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
CARVYKTI is an Oncology drug manufactured by Janssen and administered via the Intravenous route of administration. The Q Code: Q2056 is aligned to the drug CARVYKTI.